StockGuide AI
Your portfolio
EN RU ES DE IT PT FR
Ticker: NTRA

Natera

Healthcare Healthcare Medical - Diagnostics & Research
Price 267.76
Reco Sell Potential 50 Risk 69 Updated 2026-07-31
Official website

Forecast impact

positive
Target +23.2% target fill 81.1%
Reaction D5 +0.59% · D10 -2.28% fresh confirmed
Impact Potential +3 · Risk -1 valid until 2026-08-13

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Natera (NTRA.US) operates in the healthcare sector, specializing in genetic testing and diagnostics. Its core products include non-invasive prenatal testing, oncology testing, and organ transplant compatibility testing. The company primarily generates revenue from its testing services, catering to healthcare providers and patients. Natera's major business segments focus on reproductive health, oncology, and transplant diagnostics, positioning it as a significant player in the genetic testing market.

Investment Profile

Natera's investment profile is characterized by a focus on growth, appealing to investors seeking potential capital appreciation. The company is not currently providing dividends, which may not attract income-focused investors. Its performance metrics suggest a balanced approach may be suitable for those with a medium to long-term investment horizon. The stock's liquidity is moderate, making it accessible for various investor experience levels.

Category: Healthcare Sector: Healthcare Industry: Medical - Diagnostics & Research Investment style: Growth Horizon: Medium-term Company type: Mid Cap Experience: Basic 6 months
Fundamental metrics (experimental) Updated: 2026-07-28
EPS (TTM) — earnings per share for the last 12 months, $
-1.63
Revenue QoQ — quarter-over-quarter revenue growth
4.7%
20d volatility
1.8%
AI recommendation changes
Date Before After Reason
2026-07-25 Hold Sell Weak fundamentals and negative momentum raise concerns.
2026-06-18 — Hold Weak fundamentals with uncertain market conditions.
Analyst forecasts
Date Analyst Action Target Price Then
2026-07-14 Canaccord Genuity Target Raised 285 → 330 272.89
2026-07-09 Morgan Stanley Target Raised 250 → 310 274.39
2026-07-06 Evercore ISI Target Raised 270 → 300 281.26
News Page 1 of 1
Natera Alibaba Grab Holdings Cadence Design Systems Apple

Analysts Morgan Stanley recommend buying Alibaba (BABA), Grab (GRAB), Cadence Design Systems (CDNS), and Natera (NTRA) ahead of earnings

07/25/2026, 06:32 AM investing recommendation Analysts: analysts, Morgan Stanley software consumer Natera Alibaba Grab Holdings Cadence Design Systems Apple
Morgan Stanley identifies several stocks, including Alibaba and Grab, as having significant upside potential ahead of their upcoming earnings reports, suggesting investors consider these opportunities despite recent price fluctuations.